scholarly journals Genetic Polymorphism of Matrix Metalloproteinase-9 and Susceptibility to Myocardial Infarction: A Meta-Analysis

2022 ◽  
Vol 2022 ◽  
pp. 1-8
Author(s):  
Beili Feng ◽  
Hengdong Li

Objective. Current findings on the association between MMP-9 rs3918242 and susceptibility to myocardial infarction (MI) are inconsistent, and their definite relationship is discussed in this meta-analysis. Methods. Eligible literatures reporting MMP-9 rs3918242 and susceptibility to MI were searched in PubMed, Cochrane Library, CNRI, and VIP using keywords such as “MMP-9”, “matrix metallopeptidase-9” and “myocardial infarction”, “acute myocardial infarction”, “AMI”, and “polymorphism”. Data from eligible literatures were extracted for calculating OR and corresponding 95% CI using RevMan 5.3 and STATA12.0. Results. Ten independent literatures reporting MMP-9 rs3918242 and susceptibility to MI were enrolled. Compared with subjects carrying CT&TT genotype of MMP-9 rs3918242, susceptibility to MI was lower in those carrying CC genotype ( OR = 1.49 , 95 % CI = 1.19 – 1.86 , P = 0.0004 ). Such a significance was observed in the overdominant ( OR = 1.27 , 95 % CI = 1.14 – 1.41 , P < 0.0001 ) and allele genetic models ( OR = 1.43 , 95 % CI = 1.17 – 1.74 , P = 0.0005 ) as well. This finding was also valid in the Asian population. Conclusions. Mutation on MMP-9 rs3918242 has a potential relevance with susceptibility to MI.

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e044564
Author(s):  
Kaizhuang Huang ◽  
Jiaying Lu ◽  
Yaoli Zhu ◽  
Tao Cheng ◽  
Dahao Du ◽  
...  

IntroductionDelirium in the postoperative period is a wide-reaching problem that affects important clinical outcomes. The incidence and risk factors of delirium in individuals with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI) has not been completely determined and no relevant systematic review and meta-analysis of incidence or risk factors exists. Hence, we aim to conduct a systematic review and meta-analysis to ascertain the incidence and risk factors of delirium among AMI patients undergoing PCI.Methods and analysesWe will undertake a comprehensive literature search among PubMed, EMBASE, Cochrane Library, PsycINFO, CINAHL and Google Scholar from their inception to the search date. Prospective cohort and cross-sectional studies that described the incidence or at least one risk factor of delirium will be eligible for inclusion. The primary outcome will be the incidence of postoperative delirium. The quality of included studies will be assessed using a risk of bias tool for prevalence studies and the Cochrane guidelines. Heterogeneity of the estimates across studies will be assessed. Incidence and risk factors associated with delirium will be extracted. Incidence data will be pooled. Each risk factor reported in the included studies will be recorded together with its statistical significance; narrative and meta-analytical approaches will be employed. The systematic review and meta-analysis will be presented according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.Ethics and disseminationThis proposed systematic review and meta-analysis is based on published data, and thus there is no requirement for ethics approval. The study will provide an up to date and accurate incidence and risk factors of delirium after PCI among patients with AMI, which is necessary for future research in this area. The findings of this study will be disseminated through publication in a peer-reviewed journal.PROSPERO registration numberCRD42020184388.


Cardiology ◽  
2019 ◽  
Vol 144 (3-4) ◽  
pp. 69-75
Author(s):  
Shangbo Xu ◽  
Lihua Yang ◽  
Danhua Hong ◽  
Lan Chen ◽  
Xin Wang

Several studies have indicated that early repolarization (ER) is a risk factor for ventricular tachyarrhythmias (VTAs) in acute myocardial infarction (AMI) patients. The prognostic values of ER detail characteristics except J-point morphology, and inferior leads ER location for VTAs are still unclear. We searched PubMed, Embase, and the Cochrane Library for eligible studies up to March 4, 2019. Studies to investigate the relationship between ER and the incidence of VTAs in AMI patients were extracted. A total of 10 studies with 2,672 participants were included in the analysis. ER significantly predicted the incidence of VTAs (odds ratio [OR] 3.62, 95% confidence intervals [CI] 2.77–4.73), regardless of the type of AMI. The presence of ER before AMI (OR 5.58, 95% CI 3.41 to 9.12) and after AMI (OR 3.02, 95% CI 2.19–4.15) increased the risk of VTAs. The prognostic value of ER for VTAs in the long follow-up (≥30 days) (OR 2.39, 95% CI 1.59–3.59) fell by half compared to the short follow-up duration (<30 days) (OR 4.97, 95% CI 3.48–7.09). Patients with ER displayed a higher risk of developing ventricular fibrillation (VF) (OR 6.94, 95% CI 3.87–12.43) than those without ER. However, neither J-point elevation with OR = 2.48 nor lateral leads’ ER location with OR = 3.83 remarkably increased the risk of VTAs in patients with AMI. ER is significantly associated with increasing risk of VTAs, particularly VF, in AMI patients. This relationship is weaker in the 30-day follow-up and is not reinforced by J-point elevation and lateral leads’ ER location.


2021 ◽  
Author(s):  
Maria del Carmen Caycho Torres ◽  
Johnny Clavo Yamahuchi ◽  
Cory Cornejo Ramos ◽  
Katherine Ada Diaz Gomez ◽  
Omar Zanoni Ramos ◽  
...  

Background: Cardiovascular diseases represent important diagnoses that can become fatal if an early and adequate management is not carried out. Since 1930, a possible relationship between these events and influenza virus infection has been proposed. Objectives: To determine the association between cardiovascular diseases and previous infection by influenza virus. Materials and methods: A systematic review was carried out according to PRISMA. The electronic search was carried out in the databases of EMBASE, PubMed, Global Index Medicus, Google Scholar and Cochrane Library. The included studies had laboratory-confirmed influenza in patients over 18 years of age; studies that considered pregnant patients or animals were excluded. The quality of the studies was verified using the standardized tool of the National Heart Lung and Blood Institute and the certainty of the results was assessed with GRADE. In addition, 2 meta-analysis of the association measures were performed using the Cochrane Software Review Manager 5.4.1. Results: 31 records were identified, of which 4 were included (n = 1101). These studies were conducted in Finland, China, and Australia. The estimated combined OR for the positive association between influenza A and acute myocardial infarction obtained was 2.52 (95% CI 1.59 - 4); and in the association with influenza B, an OR of 4.78 ( 95% CI 1.57-14.61). The OR obtained for the association with myocarditis was 5.23 (95% CI 1.00 - 27.32). Conclusions: Evidence of almost 5 times the risk of suffering acute myocardial infarction was found in those who had a previous episode of influenza B, and almost 3 with influenza A. Better quality longitudinal studies are required to confirm this finding.


2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Jingyi Zhao ◽  
Hairong Yu ◽  
Peng Yan ◽  
Xiaohui Zhou ◽  
Ying Wang ◽  
...  

Background. Recent studies have shown that circulating microRNA-499 could be a powerful biomarker of acute myocardial infarction (AMI). Interest in circulating microRNA-499 for detecting AMI is increasing rapidly. To evaluate the diagnosis of circulating microRNA-499 for AMI, this study was performed. Methods. We searched PubMed, Embase, and the Cochrane Library for studies published up to December 31, 2018, as well as the reference lists of relevant studies. Studies were included if they assessed the accuracy of blood circulating microRNA-499 or cardiac troponin T (cTnT) for AMI and provided sufficient data to construct a 2×2 contingency table. Extracted data were analysed for sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operator curve (SROC) analyses. Prespecified subgroup analysis and metaregression were also performed. Results. Fourteen studies including 3816 participants were included in this meta-analysis. The overall pooled sensitivity and specificity were 0.84 (95% CI: 0.64-0.94) and 0.97 (95% CI: 0.90-0.99), respectively. The area under the SROC curve (AUC) was 0.98 (95% CI: 0.96-0.99). The studies had substantial heterogeneity (I2=98.74%). Seven studies also used cTnT as a marker for the diagnosis of AMI. The overall pooled sensitivity and specificity of cTnT were 0.95 (95% CI: 0.87-0.98) and 0.96 (95% CI: 0.85-0.99), respectively. The area under the SROC curve (AUC) was 0.99 (95% CI: 0.97-0.99). The DOR of circulating miR-499 and cTnT were 188 (95% CI: 19-1815) and 420 (95% CI: 86-2038), respectively. Metaregression analysis suggested that specimen and healthy controls were the main sources of heterogeneity. No publication bias was suggested by Deeks’ regression test of asymmetrical funnel plot (t=0.85; p value = 0.41). Conclusion. The results showed that circulating microRNA-499 is a reliable biomarker for diagnosing AMI patients.


2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Bei Liu ◽  
Chong-Yang Duan ◽  
Cheng-Feng Luo ◽  
Cai-Wen Ou ◽  
Zhi-Ye Wu ◽  
...  

Background. The optimal timing for Bone Marrow Stem Cells (BMCs) therapy following acute myocardial infarction (AMI) remains unclear.Aims. To synthesize the evidence from trials using a multiple-treatment comparison method, thereby permitting a broader comparison across multiple timing of BMCs therapy.Methods and Results. Randomized controlled trials in patients with AMI receiving BMCs therapy were identified from PubMed, Ovid LWW, BIOSIS Previews, and the Cochrane Library through January 2015. 2 035 patients of 31 studies included in our analysis were allocated to 5 groups’ treatments: 1~3 days, 4~7 days, 8~14 days, 15~30 days, or placebo/control group. The multiple-treatment meta-analysis showed that 4~7 days’ group could lead to significantly increased left ventricular ejection fraction (LVEF) as compared with control (mean of MDs and 95% CI: 6 months, 3.05 (0.92~5.25); 12 months, 4.18 (2.30~5.84)). Only 4~7 days led to significant reduction of MACEs compared with control (OR and 95% CI 0.34 (0.13~0.96)) for 12-months follow-up. In simulated comparisons, the 4~7 days’ group ranked better than other timing groups for improvement of LVEF or reduction of the incidence of major adverse cardiac events.Conclusions. 4~7 days after AMI might be the optimal timing for cell therapy in terms of efficacy or safety.


2016 ◽  
Vol 21 (6) ◽  
pp. 604-612 ◽  
Author(s):  
Barış Güngör ◽  
Kazım Serhan Özcan ◽  
Mehmet Baran Karataş ◽  
İrfan Şahin ◽  
Recep Öztürk ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document